OCU410
Study Overview
This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (AMD).
This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 63 subjects.
Study title
A Phase 1/2 Study to Assess the Safety And Efficacy Of OCU410 For Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration
Medical Condition(s)
Geographic Atrophy
Product
AAV-hRORA
OCUGEN PROTOCOL NUMBER
OCU410-101
NUMBER OF SUBJECTS
Up to 63 adults who meet eligibility criteria
STUDY LENGTH
12 months
SEX
Male & Female
STUDY DATES
AGE
18+
PHASE
1/2
COUNTRY
United States